Trending

M42, Zayed Authority, and NMC Healthcare Collaborate on Genetic Testing for Children

Abu Dhabi:M42, the Zayed Authority for People of Determination, and NMC Healthcare have signed a Memorandum of Understanding (MoU) to advance genetic testing and research for children supported by the Mowj Early Intervention Centre. This strategic partnership aims to enhance the understanding of neurodevelopmental disorders and developmental delays, facilitating more personalized clinical care and early intervention.

According to Emirates News Agency, the MoU outlines that M42 will conduct genetic testing and contribute to research efforts, which include sample collection, laboratory analysis, and sharing results under agreed governance and privacy frameworks. Additionally, M42 will focus on research into genetic factors associated with neurodevelopmental conditions.

NMC Healthcare's role involves managing informed consent, providing genetic counseling, communicating results, and supporting clinical care planning through its specialist teams. Meanwhile, the Zayed Authority for People of Determination will offer strategic oversight, beneficiary support, and coordination with relevant authorities to ensure the initiative aligns with regulatory requirements and meets families' needs.

The collaboration will also explore future applications of precision medicine. By connecting genomic science with early intervention and rehabilitation services, the three organizations aim to offer more informed, individualized care for children and their families.

Abdulla Abdulalee Al Humaidan, Acting Director-General of the Zayed Authority, emphasized the potential of genetic science to advance medical knowledge and support clinical decision-making tailored to each child's needs. Dr. David Kavanagh of M42 highlighted the initiative's goal to make advanced genomic science accessible to families, enhancing the understanding of children's health conditions through genetic testing.

Frank DeLisi of NMC Healthcare noted that the partnership opens new opportunities for clinical innovation and participation in genetic research, contributing to precision medicine applications. The agreement builds on previous collaborations between M42 and the Zayed Authority, extending genomic insights to early intervention services within approved medical frameworks.

Recent Post

Advertisement